Journal of the Royal Society of Medicine, Vol 78, Issue 10 826-829, Copyright © 1985 by Royal Society of Medicine
ORIGINAL ARTICLES |
A Forbes, PJ Johnson and R Williams
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
This article has been cited by other articles:
![]() |
A. M. DI BISCEGLIE, V. K. RUSTGI, J. H. HOOFNAGLE, G. M. DUSHEIKO, and M. T. LOTZE Hepatocellular Carcinoma Ann Intern Med, March 1, 1988; 108(3): 390 - 401. [Abstract] [PDF] |
||||